Immunex Novantrone
Executive Summary
Supplemental NDA filed June 3 for secondary progressive multiple sclerosis indication. Immunex is requesting a priority review. Novantrone (mitoxantrone) reduced by 21% the relapse rate and disability progression in 194 patients with secondary progressive multiple sclerosis, according to results of a two-year pivotal trial. Third-year follow-up results demonstrated sustained reduction. Novantrone is approved for treatment of pain in patients with advanced hormone-refractory prostate cancer and for initial therapy of acute non-lymphocytic leukemia
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth